4D Molecular Therapeutics (FDMT)

Executive Summary

4D Molecular Therapeutics (FDMT) is a clinical-stage gene therapy company leveraging its proprietary directed evolution platform to engineer optimized AAV vectors for improved tissue targeting and reduced immunogenicity. The lead asset, 4D-150, is in Phase 3 for wet age-related macular degeneration (nAMD) and Phase 2 for diabetic macular edema (DME), with the potential to dramatically reduce injection burden. Additional programs include 4D-310 for Fabry disease (Phase 1/2) and 4D-710 for cystic fibrosis (Phase 2). With a market cap of ~$530M, 4DMT is well-positioned for multiple value-driving catalysts over the next 12-24 months.

Upcoming Catalysts (preview)

• Q4 2027Top-line data from Phase 3 4D-150 in wet AMD (PRISM trial)60% success
• H1 2027Phase 2 data for 4D-150 in diabetic macular edema (DME)50% success
• H2 2026Phase 2 interim data for 4D-710 in cystic fibrosis lung disease40% success